Kevin Donohue, DO
Internal Medicine · Falls Church, VANPI 1366604555
Payments from drug & device makers
Across 1,683 payments — averaging $389.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$605K
- Boehringer Ingelheim$14K
- Ascendis Pharma Endocrinology Inc$13K
- AstraZeneca$5K
- Senseonics, Incorporated$4K
- Tolmar, Inc.$3K
- plus $10K from 47 others
What the payments were for
- Consulting fees$9,0751%
- Speaking & faculty fees$592,57791%
- Travel & lodging$30,9725%
- Food & beverage$21,9493%
- Education$1690%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$297,490
- TRULICITY$246,607
- JARDIANCE$46,921
- Yorvipath$9,282
- FARXIGA$4,800
- Eversense$4,130
- JATENZO$3,055
- TWIIST$250
- TOUJEO$241
- Prokera$170
- FREESTYLE LIBRE 3$150
- SOLIQUA 100/33$129
- Wegovy$125
- Levemir$125
- NovoLog$125
- NovoLog Mix 70/30$125
- EVENITY$125
- TEPEZZA$125
- ZEPBOUND$119
- t:slim X2 Insulin Pump with Control-IQ$118
How this compares
$654,741 in reported general payments places this provider in the 95th percentile of 2,724 internal medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 231 | $273,776 |
| OzempicSemaglutide | 165 | $228,792 |
| TrulicityDulaglutide | 130 | $178,550 |
| JardianceEmpagliflozin | 85 | $112,798 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 39 | $64,040 |
| FarxigaDapagliflozin Propanediol | 29 | $36,174 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 19 | $32,367 |
| GlyxambiEmpagliflozin/Linagliptin | 20 | $24,284 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 14 | $19,421 |
| SynthroidLevothyroxine Sodium | 156 | $16,336 |
| JatenzoTestosterone Undecanoate | 14 | $16,019 |
| JanuviaSitagliptin Phosphate | 14 | $15,413 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 11 | $12,545 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $11,784 |
| Cinacalcet Hcl | 14 | $8,548 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $604,922 | $452,327361 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Trijardy Xr, Glyxambi | $14,041 | $233,489163 claims |
| Novo NordiskOzempic | $1,306 | $228,792165 claims |
| AstraZenecaFarxiga | $5,167 | $36,17429 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $1,211 | $19,42114 claims |
| AbbVieSynthroid, Armour Thyroid | $111 | $18,381179 claims |
| Clarus Therapeutics Inc.Jatenzo | $10 | $16,01914 claims |
| IBSA Pharma Inc.Tirosint | $59 | $4,75322 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $525 | $2,760194 claims |
| PfizerLevoxyl | $120 | $52117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 internal medicine providers in Virginia.
Other internal medicine in Falls Church
- Amit MahajanFalls Church$1.3M
- Anu GeorgeFalls Church$547K
- Sheinei AlanFalls Church$352K
- Leroy VaughanRichmond$20.8M
- James ClarkCharlottesville$16.2M
- Nabil AndrawisBurke$8.5M
- Mary BlumbergNorfolk$6.5M
- David RamstadSuffolk$5.8M
- Andrew PoklepovicRichmond$4.6M
- Nashwa GabraBurke$4.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.